1. Introduction
===============

Knee osteoarthritis is a chronic degenerative bone metabolic disease that commonly occurs in middle-aged and older adults; it affects patients' daily activities and even causes disability.^\[[@R1],[@R2]\]^ Its clinical features mainly include cartilage degenerative lesions, with clinical manifestations such as joint swelling, pain, and deformity. Thus, the main therapeutic purposes of knee osteoarthritis are to reduce or eliminate pain, correct joint deformities, and improve joint function through cartilage repair.^\[[@R3]\]^

In recent years, replacement of damaged articular cartilage by chondrocytes or cartilage tissue has been considered a potential approach for treating knee osteoarthritis. Studies have shown that it is feasible to induce human pluripotent stem cells to differentiate into chondrocytes; therefore, stem cell therapy has become a new method for local treatment of knee osteoarthritis. For example, mesenchymal stem cells (MSCs) have multi-directional differentiation potential and can be differentiated into osteoblasts and chondrocytes under specific induction conditions in vitro and in vivo, thereby repairing bone and articular cartilage.^\[[@R4],[@R5]\]^ However, there is still a dispute on the clinical effects of stem cells,^\[[@R6]--[@R8]\]^ for which a multitude of clinical trials and meta-analyses have been conducted.^\[[@R9],[@R10]\]^

We herein present a meta-analysis of the controversial efficacy and safety of stem cell therapy as a clinical treatment of knee osteoarthritis. This study is markedly distinguished from previous meta-analyses^\[[@R9],[@R10]\]^ because it focused on bone marrow MSCs, peripheral blood stem cells, and amniotic fluid free stem cells. In addition, we used updated data from several latest high-level randomized controlled trials (RCTs).^\[[@R11],[@R12]\]^ This meta-analysis is expected to provide an evidence of the efficacy of stem cell therapy as a conservative treatment of knee osteoarthritis.

2. Methods
==========

All analyses were based on previous published studies; thus, no ethical approval and patient consent are required.

2.1. Study selection
--------------------

In accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement,^\[[@R13]\]^ 2 researchers independently screened the literature, as well as extracted and cross-checked the relevant data. If disagreements occurred, a decision regarding data extraction was made by a third researcher.

2.2. Search strategy
--------------------

We conducted the search in PubMed (1970-May 2019), Embase (1970-May 2019), and The Cochrane Library (1970-May 2019) databases for relevant articles, with "stem cells" and "osteoarthritis" as search terms. We also manually screened relevant Chinese and English language journals and reference lists to include potential studies. The search strategy for PubMed is detailed herein as an example: ((("Stem Cells"\[Mesh\]) OR ((((((((((((((Cell, Stem\[Title/Abstract\]) OR Stem Cell\[Title/Abstract\]) OR Progenitor Cells\[Title/Abstract\]) OR Cell, Progenitor\[Title/Abstract\]) OR Cells, Progenitor\[Title/Abstract\]) OR Progenitor Cell\[Title/Abstract\]) OR Mother Cells\[Title/Abstract\]) OR Cell, Mother\[Title/Abstract\]) OR Cells, Mother\[Title/Abstract\]) OR Mother Cell\[Title/Abstract\]) OR Colony-Forming Unit\[Title/Abstract\]) OR Colony Forming Unit\[Title/Abstract\]) OR Colony-Forming Units\[Title/Abstract\]) OR Colony Forming Units\[Title/Abstract\]))) AND ((((((((((((((Osteoarthritides\[Title/Abstract\]) OR Osteoarthrosis\[Title/Abstract\]) OR Osteoarthroses\[Title/Abstract\]) OR Arthritis, Degenerative\[Title/Abstract\]) OR Arthritides, Degenerative\[Title/Abstract\]) OR Degenerative Arthritides\[Title/Abstract\]) OR Degenerative Arthritis\[Title/Abstract\]) OR Osteoarthrosis Deformans\[Title/Abstract\]) OR Polyarthritides\[Title/Abstract\]) OR Arthritides\[Title/Abstract\]) OR Polyarthritis\[Title/Abstract\]) OR Arthritis\[Title/Abstract\])) OR "Osteoarthritis"\[Mesh\]).

2.3. Eligibility criteria
-------------------------

The study inclusion criteria included:

1.  studies involving patients with knee osteoarthritis;

2.  studies including stem cell therapy as the test group, as well as placebo, hyaluronic acid, and steroid treatments as the control groups;

3.  RCTs;

4.  studies that used at least one of the following indicators: Visual Analogue Scale (VAS) score, Western Ontario and McMaster Universities (WOMAC) subscale, International Knee Documentation Committee (IKDC) score, and incidence of adverse events.

Studies were ineligible if they met any of the following conditions:

1.  studies that used animals or cadavers as research objects;

2.  studies that were unable to extract or convert valid data;

3.  retrospective studies, literature reviews, or conference papers with no full text.

2.4. Data extraction
--------------------

Data were extracted independently by 2 researchers using a predesigned data sheet. Valid data were converted as per the Cochrane Handbook for Systematic Reviews of Interventions,^\[[@R14]\]^ in the case where standard deviation could not be acquired. If disagreements occurred, the decision regarding data extraction was done by the third reviewer. Each RCT was concurrently assessed with risk of bias.

2.5. Outcome measures
---------------------

-   VAS is a scoring scale that intuitively quantifies the intensity of pain in the knee. A lower score indicates milder pain.

-   The WOMAC subscale is a rating scale that assesses the structure, stiffness, and function of the knee in pain A lower score indicates better knee condition.

-   IKDC is a subjective scale for assessing the knee joint. A higher score indicates better symptoms, functions, and physical activities of the knee joint.

-   Adverse events refer to treatment-related adverse reactions, including joint effusion, stiffness, and pain.

2.6. Statistical analysis
-------------------------

Statistical analysis was conducted using the RevMan 5.3 software (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014). The chi-square test was used to assess inter-study heterogeneity. I^2^ \> 50% indicated heterogeneity. A random effects model was used; otherwise, a fixed effects model was used. Relative risk and standardized mean difference were used for assessing binary variables and continuous variables, respectively. The 95% confidence interval estimates and hypothesis testing results for each variable were listed in a forest plot. For each endpoint with high heterogeneity, a sensitivity analysis, in which the included studies were removed one at a time, was conducted to screen the source of heterogeneity. A publication bias assessment using a funnel plot was performed if there were no less than 10 studies included.

3. Results
==========

3.1. Literature search
----------------------

We retrieved 7054 relevant articles, and ultimately included 9 RCTs^\[[@R11],[@R12],[@R15]--[@R21]\]^ involving 399 patients (Fig. [1](#F1){ref-type="fig"}). In the studies by Kuah,^\[[@R12]\]^ Lamo-Espinosa,^\[[@R16]\]^ and Thomas Vangsness et al,^\[[@R19]\]^ there were 2 parallel test groups, namely the high- and low-dose groups, in comparison with the control group. Therefore, for each study mentioned above, we conducted statistical analyses in 2 RCTs: high-dose vs control and low-dose vs control.
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3.2. Study characteristics
--------------------------

There were 203 patients in the stem cell therapy group and 196 patients in the control group. The specific features and Jadad scores of the patients^\[[@R22],[@R23]\]^ are listed in Table [1](#T1){ref-type="table"}. The Jadad scale is a 7-point scale that includes random sequence generation, randomized hiding, blind method, withdrawal, and dropout.

###### 

Main characteristics of all the eligible studies included in the analysis.

![](medi-99-e19434-g002)

3.3. Clinical outcomes
----------------------

### 3.3.1. VAS

From baseline to 3 months, 4 studies^\[[@R12],[@R15],[@R16],[@R20]\]^ were included, involving 6 RCTs with 87 patients in the stem cell group and 79 patients in the control group Fig. [2](#F2){ref-type="fig"}. There was no heterogeneity (I^2^ = 0%) between the studies; thus, the fixed effects model was used for the analysis. According to Figure [2](#F2){ref-type="fig"}, SMD (standardized mean difference) = −0.36, 95% CI (confidence interval)\[−0.67, −0.05\], and *P* = .02. The VAS score in the stem cell group was significantly lower than that in the control group.

![Forest plot of the change of VAS score. VAS = visual analogue scale score.](medi-99-e19434-g003){#F2}

From baseline to 6 months, 4 studies^\[[@R12],[@R15],[@R16],[@R20]\]^ were included, involving 6 RCTs with 87 patients in the stem cell group and 79 patients in the control group. Because there was a high heterogeneity (I^2^ = 86%) between the studies, the study by Bhattacharya et al^\[[@R20]\]^ was removed from the sensitivity analysis, and the I^2^ value was reduced to 0%. The fixed effects model was used. According to Figure [2](#F2){ref-type="fig"}, SMD = −0.86, 95% CI \[−1.21, −0.52\], and *P* \< .00001. The VAS score in the stem cell group was significantly lower than that in the control group.

From baseline to 12 months, 3 studies^\[[@R12],[@R16],[@R21]\]^ were included, involving 5 RCTs with 51 patients in the stem cell group and 43 patients in the control group. There was a low heterogeneity (I^2^ = 8%) between the studies, and thus the fixed effects model was used. According to Figure [2](#F2){ref-type="fig"}, SMD = −0.86, 95% CI \[−1.30, −0.43\], and *P* = 0.0001. The VAS score in the stem cell group was significantly lower than that in the control group.

### 3.3.2. WOMAC-Pain

From baseline to 3 months, 2 studies^\[[@R12],[@R16]\]^ were included, involving four RCTs with 36 patients in the stem cell group and 28 patients in the control group Fig. [3](#F3){ref-type="fig"}. There was a low heterogeneity (I^2^ = 40%) between the studies, and thus the fixed effects model was used. According to Figure [3](#F3){ref-type="fig"}, SMD = −0.22, 95% CI \[−0.73, 0.30\], and *P* = .41. There was no significant difference in WOMAC-Pain score between the groups.
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From baseline to 6 months, 2 studies^\[[@R12],[@R16]\]^ were included, involving four RCTs with 36 patients in the stem cell group and 28 patients in the control group. There was a low heterogeneity (I^2^ = 48%) between the studies, and thus the fixed effects model was used. According to Figure [3](#F3){ref-type="fig"}, SMD = −0.08, 95% CI \[−0.59, 0.44\], and *P* = .77. There was no significant difference in WOMAC-Pain score between the groups.

From baseline to 12 months, 3 studies^\[[@R12],[@R16]\]^ were included, involving 4 RCTs with 43 patients in the stem cell group and 39 patients in the control group. There was no heterogeneity (I^2^ = 0%) between the studies, and thus the fixed effects model was used. According to Figure [3](#F3){ref-type="fig"}, SMD = −0.09, 95% CI \[−0.53, 0.36\], and *P* = .70. There was no significant difference in WOMAC-Pain score between the groups.

### 3.3.3. WOMAC-Stiffness

From baseline to 3 months, 2 studies^\[[@R12],[@R16]\]^ were included, involving 4 RCTs with 36 patients in the stem cell group and 28 patients in the control group Fig. [4](#F4){ref-type="fig"}. There was no heterogeneity (I^2^ = 0%) between the studies, and the fixed effects model was used. According to Figure [4](#F4){ref-type="fig"}, SMD = −0.51, 95% CI \[−1.02, 0.01\], and *P* = .05. There was no significant difference in WOMAC-Stiffness score between the groups.

![Forest plot of the change of WOMAC-Stiffness score. WOMAC = Western Ontario and McMaster Universities subscore.](medi-99-e19434-g005){#F4}

From baseline to 6 months, 2 studies^\[[@R12],[@R16]\]^ were included, involving four RCTs with 36 patients in the stem cell group and 28 patients in the control group. There was a low heterogeneity (I^2^ = 36%) between the studies, and the fixed effects model was used. According to Figure [4](#F4){ref-type="fig"}, SMD = −0.25, 95% CI \[−0.76, 0.27\], and *P* = .35. There was no significant difference in WOMAC-Stiffness score between the groups.

From baseline to 12 months, 2 studies^\[[@R12],[@R16]\]^ were included, involving 4 RCTs with 36 patients in the stem cell group and 28 patients in the control group. There was a low heterogeneity (I^2^ = 9%) between the studies, and the fixed effects model was used. According to Figure [4](#F4){ref-type="fig"}, SMD = −0.46, 95% CI \[−0.98, 0.05\], and *P* = .08. There was no significant difference in WOMAC-Stiffness score between the groups.

### 3.3.4. WOMAC-Function

From baseline to 3 months, 2 studies^\[[@R12],[@R16]\]^ were included, involving 4 RCTs with 36 patients in the stem cell group and 28 patients in the control group Fig. [5](#F5){ref-type="fig"}. There was no heterogeneity (I^2^ = 0%) between the studies, and the fixed effects model was used. According to Figure [5](#F5){ref-type="fig"}, SMD = 0.15, 95% CI \[−0.35, 0.66\], and *P* = .55. There was no significant difference in WOMAC-Function score between the groups.
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From baseline to 6 months, 2 studies^\[[@R12],[@R16]\]^ were included, involving four RCTs with 36 patients in the stem cell group and 28 patients in the control group. There was a low heterogeneity (I^2^ = 29%) between the studies, and the fixed effects model was used. According to Figure [5](#F5){ref-type="fig"}, SMD = 0.43, 95% CI \[−0.09, 0.95\], and *P* = .1. There was no significant difference in WOMAC-Function score between the groups.

From baseline to 12 months, 2 studies^\[[@R12],[@R16]\]^ were included, involving 4 RCTs with 36 patients in the stem cell group and 28 patients in the control group. There was no heterogeneity (I^2^ = 0%) between the studies, and the fixed effects model was used. According to Figure [5](#F5){ref-type="fig"}, SMD = 0.18, 95% CI \[−0.33, 0.68\], and *P* = .49. There was no significant difference in WOMAC-Function score between the groups.

### 3.3.5. IKDC

From baseline to 6 months, 2 studies^\[[@R17],[@R18]\]^ were included, involving 2 RCTs with 53 patients in the stem cell group and 52 patients in the control group Fig. [6](#F6){ref-type="fig"}. There was a high heterogeneity (I^2^ = 51%) between the studies, and the random effects model was used. According to Figure [6](#F6){ref-type="fig"}, SMD = 0.16, 95% CI \[−0.39,0.72\], and *P* = .56. There was no significant difference in IKDC score between the groups.
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From baseline to 12 months, 2 studies^\[[@R17],[@R18]\]^ were included, involving 2 RCTs with 53 patients in the stem cell group and 52 patients in the control group. There was a high heterogeneity (I^2^ = 83%) between the studies, and the random effects model was used. According to Figure [6](#F6){ref-type="fig"}, SMD = 0.36, 95% CI \[−0.58, 1.31\], and *P* = .45. There was no significant difference in IKDC score between the groups.

From baseline to 24 months, 2 studies^\[[@R17],[@R18]\]^ were included, involving 2 RCTs with 53 patients in the stem cell group and 52 patients in the control group. There was a high heterogeneity (I^2^ = 75%) between the studies, and the random effects model was used. According to Figure [6](#F6){ref-type="fig"}, SMD = 0.53, 95% CI \[−0.25, 1.32\], and *P* = .18. There was no significant difference in IKDC score between the groups.

### 3.3.6. Adverse events

There were 2 included studies,^\[[@R11],[@R12]\]^ involving three RCTs with 28 patients in the stem cell group and 20 patients in the control group Fig. [7](#F7){ref-type="fig"}. There was a high heterogeneity (I^2^ = 73%) between the studies, and thus the random effects model was used. According to Figure [7](#F7){ref-type="fig"}, SMD = 1.54, 95% CI \[0.57, 4.19\], and *P* = .40. There was no significant difference in incidence of adverse events between the groups.
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4. Discussion
=============

4.1. Key findings
-----------------

Changes in VAS and IKDC scores from baseline to 24 months were superior in the stem cell group than in the control group, whereas there were no statistical differences in the changing trend of other indicators between the 2 groups, including the changes in IKDC scores at 6 months, IKDC score at 12 months, WOMAC-Pain score, WOMAC-Stiffness score, WOMAC-Function score, WOMAC-Pain score, and incidence of adverse events.

Pain relief is key to treating knee osteoarthritis, with VAS scores as an important endpoint for pain assessment. Kuah et al^\[[@R12]\]^ found that relative to placebo, stem cell therapy considerably relieved pain at 3, 6, and 12 months after treatment. This conclusion has been confirmed in our meta-analysis. We found that the VAS scores in the stem cell group were significantly reduced at each visit point. Inflammatory response is known as one of the causes of pain. MSCs can release anti-inflammatory factors, thereby relieving pain. Lamo-Espinosa et al^\[[@R16]\]^ believed that stem cells have a paracrine function and their anti-inflammatory properties contribute to pain relief. In addition, studies have found that in an acute renal failure model, MSCs can promote recovery of renal function by releasing anti-inflammatory factors and inhibiting production of pro-inflammatory cytokines, such as interleukin-1β, tumor necrosis factor, and interferon-γ.^\[[@R24]\]^ Similar findings were observed in a pulmonary fibrosis model, in which MSCs release IL-1 receptor antagonist (IL-1RA) to inhibit interleukin-1α-producing T cells and TNF-producing macrophages, indicating that MSCs have anti-inflammatory properties.^\[[@R25]\]^ WOMAC-Pain scores showed no statistical difference between the 2 groups at each visit point, but these data regarding WOMAC-Pain score were obtained only from 3 studies;^\[[@R12],[@R16],[@R21]\]^ therefore, further studies with larger sample sizes are warranted to verify these findings.

Functional improvement of the knee joint is one of the ultimate purposes of knee osteoarthritis treatment. In this study, we used WOMAC-Stiffness, WOMAC-Function, and IKDC scores to comprehensively assess knee joint function. Statistical analysis results showed that there was no significant difference between the 2 groups in IKDC scores at 6 and 12 months, as well as in WOMAC-Stiffness and WOMAC-Function scores at each visit point. Studies have found that mesenchymal stem cell implantation achieves better outcomes in patients with grade 3 knee osteoarthritis than those in patients with grade 4 knee osteoarthritis.^\[[@R26]\]^ We thus concluded that treatment with MSCs are effective in preventing or limiting the progression of knee osteoarthritis at the early stage. In the studies by Kuah^\[[@R12]\]^ and Lamo-Espinosa et al,^\[[@R16]\]^ patients with grade 3 osteoarthritis or higher accounted for 75% and over 80% of the total patients, respectively. Most patients developed knee osteoarthritis at the middle and late stages, for whom treatment with MSCs had no significant efficacy and was not conducive to functional recovery. Moreover, in most tissue engineering methods, MSCs are combined with cell scaffolds containing chondrogenic growth factors to form fully functional hyaline cartilage. Such a regimen is commonly used in small-animal models of surgically induced cartilage or osteochondral defects, but cannot be used for repairing large-area cartilage defects associated with knee osteoarthritis.^\[[@R27]\]^ In addition, Centeno,^\[[@R28]\]^ Emadedin,^\[[@R29]\]^ and Vangsness et al^\[[@R19]\]^ pointed out that treatment with approximately 2 × 10^7^ stem cells can afford good clinical results. Kuah^\[[@R12]\]^ and Lamo-Espinosa et al^\[[@R16]\]^ reported that a stem cell dose of lower or higher than 2 × 10^7^ may also impact the therapeutic efficacy of stem cells. In addition, the change in IKDC score at 24 months was higher in the stem cell group than in the control group; however, these data were extracted from only 2 studies. Therefore, further investigation with a larger sample size is warranted.

For adverse events, we sent an e-mail to the authors of the relevant research^\[[@R18],[@R19],[@R21]\]^ to obtain data on the number of patients who experienced treatment-related adverse events, including arthralgia, joint effusion, and joint stiffness, in both the stem cell and control groups. Because of the lack of response from the other studies, only 2 studies^\[[@R11],[@R12]\]^ were included, involving 3 RCTs. There were no statistical differences in adverse events between the 2 groups, indicating that stem cell treatment has no obvious side effects. A study addressing 87 patients with lupus erythematosus^\[[@R30]\]^ showed no adverse events associated with transplantation after 4 years of follow-up. Similarly, no graft-related adverse events occurred in many patients undergoing stem cell therapy for other diseases.^\[[@R31]--[@R35]\]^ These findings indicated that the human body has good tolerance to MSCs, and that stem cell treatment has no significant side effects.

4.2. Limitations
----------------

Differences in the original RCT protocols led to insufficient representation of some outcome indicators. Thus, high-quality, large-scale RCTs are required to verify our findings. In addition, there was no uniform standard in the preparation and use of stem cells, which may cause certain heterogeneity.

5. Conclusion
=============

Compared to traditional methods, stem cell treatment has a certain superiority as a conservative treatment of knee osteoarthritis, in terms of markedly reducing pain without inducing side effects.
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